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measuring albumin has a
major impact on routine
laboratory values
To the editor: In their recent study comparing different
assays to measure albumin level, van de Logt et al.1 show that
the use of bromocresol green (BCG) (but not bromocresol
purple [BCP]) leads to a substantial overestimation of plasma
and serum albumin concentration (mean bias: 6.2 g/l), in
comparison to the reference immunonephelometric assay in
patients with hypoalbuminemia (including patients with
membranous nephropathy, liver cirrhosis, or sepsis) and in
chronic kidney disease patients with albumin concentrations
within reference values. The investigators pointed out that up to
59% of patients with membranous nephropathy would receive
inappropriate prophylactic anticoagulant therapy on the basis of
albumin measured by BCG assay.
Ten years ago, we similarly demonstrated substantial
discrepancies in calcium classiﬁcation according to Kidney
Disease Outcomes Quality Initiative targets2 in 89 patients
on chronic hemodialysis, when correcting total calcium level
for albumin level measured by BCG versus BCP assay.3
Indeed, as compared with BCG, hypercalcemia was diag-
nosed in 20% of patients when albumin was measured by
BCP. Moreover 12% of patients were classiﬁed as hypocal-
cemic with BCG but had normal adjusted calcium levels
with BCP.
In conclusion, the choice of either BCG or BCP has a
major impact on several laboratory parameters (i.e., not only
albumin concentration itself but also albumin-corrected cal-
cium levels) used to manage multiple conditions. The type of
albumin assay used should be clearly indicated in any study or
clinical setting and its impact taken into account to avoid
inappropriate clinical decisions or conclusions.
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decision-making in
nephrotic syndrome patients
To the editor: With interest, we have read the article by van
de Logt et al.,1 in which the importance of albumin assays in
assessing hypoalbuminemia in nephrotic syndrome was
highlighted. The investigators conﬁrm the known bias for the
various (dye binding) albumin assays and plead for improved
standardization.
We do not believe that improved standardizing albumin
assays is the key to better management of hypoalbuminemia.
The International Federation of Clinical Chemistry/Bureau
Communitaire de Réference/College of American Patholo-
gists CRM 470 standard was a quantum leap in albumin
standardization, an approach that can hardly be improved in
the near future.
Aspeciﬁcity of colorimetric albumin assays remains an
issue that is hard to solve by standardization. Confounders
comprise carbamylation,2 uremic toxins (e.g., para-cresyl
sulfate,3 and a2-macroglobulin concentration.
4 The
altered plasma protein spectrum in nephrotic syndrome
(higher a2-macroglobulin–albumin ratio) highlights the
analytical failure of the dye binding assays. The acute
phase protein a1-acid glycoprotein
3 affects albumin test
results when using bromocresol-based dyes. The incon-
stant analytical interferences lead to variations that cannot
be corrected for by standardization. As variations in car-
bamylation and plasma protein spectra do not directly
depend on albumin concentrations, a mathematical bias
correction of albumin (as would be the case in conse-
quence of restandardization) in nephrotic syndrome is
inappropriate. In our database, the determination coefﬁ-
cient between urea and albuminemia in nephrotic syn-
drome was only 0.01.
Therefore, a robust immunochemical method (immu-
nonephelometry, immunoturbidimetry) should be the
preferred method for measuring albumin.2 Harmonization
to immunological albumin assays rather than standardi-
zation should be advocated to promote interchangeability
of test results and eventually improve treatment of
patients.
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Elsevier Inc. All rights reserved.The authors reply: We thank Dr. Delanghe and
colleagues for their valuable comments.1 We
agree that although standardization between as-
says reduces bias, it does not solve the problem
of unknown and aspeciﬁc binding of the chromogen in
patient material. Ideally, the immunological assays should
be preferred; however, the chromogen assays for albumin
measurement are widely used in clinical laboratories
worldwide at relatively low cost with highly automated
applications for the 24/7 clinical demand. The chromogen
method bromocresol purple (BCP) performs well and
outperforms BC green, in healthy persons2 as in nephrotic
patients with normal renal function, because BCP is much
less inﬂuenced by deviations in protein composition, such
as a2-macroglobulin, haptoglobin, or immunoglobulins.3
In these patients, the performance of BCP methods seems
sufﬁcient and would therefore be “ﬁt for intended use.”
Admittedly, the binding of BCP to albumin is inﬂuenced
by protein carbamylation2 and uremic toxins,4 which has
been shown in dialysis patients. The most important
lesson is that clinicians should be aware of the pitfalls of
chromogenic assays and an adequate alternative mea-
surement method should be used when necessary. The
bias introduced by protein carbamylation or uremic
toxins on the performance of the BCP assay should be
evaluated in patients with different stages of chronic
kidney disease.
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mesenchymal stromal cell-
mediated immune modulation in
renal transplant patients
To the editor: We read with great interest the B-cell analysis
by Erpicum et al.1 in kidney transplant (KTx) patients, who
were infused with third-party mesenchymal stromal cells
(MSCs) 2 to 3 days post-KTx. Based on their experience in 10
KTx patients, the investigators reported that there was a
decrease in B cells (CD19þ) in the MSC-treated group from
day 30 (D-30) until D-365. Furthermore, no change in
transitional B cells (CD19þCD24þCD38hi) was observed in
the MSC-treated group in comparison to the concurrent
control subjects.
We evaluated whether these ﬁndings were relevant to our
study, where 5 patients were given autologous MSCs 1 day
before KTx and 30 days post KTx. We followed up the
patients until the 2-year time point (D-800) and found that
there was a signiﬁcant decrease in CD19þ cell frequency in
autologous MSC-infused patients from baseline (D-0) to
D-800 (P ¼ 0.03) (Table 1).
Interestingly, for our KTx patients, we observed an
increase in transitional B-cell subset post MSC infusion
from baseline (D-0) that was maintained until D-800
(P ¼ 0.03).
We believe the variations in the ﬁndings could be attrib-
uted to the dosage, time of infusion, or the origin of the stem
cells. These ﬁndings add to current perspective of using MSCs
in KTx and explore possibilities through which immuno-
modulation can be regulated in KTx patients.249
